Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | MDG1015 |
Trade Name | |
Synonyms | MDG 1015|MDG-1015 |
Drug Descriptions |
MDG1015 is a T-cell receptor (TCR) therapy consisting of autologous T-lymphocytes engineered to express a TCR targeting NY-ESO-1 (CTAG1B),/LAGE-1a and a PD1-41BB costimulatory switch protein, which potentially induces an antitumor immune response against tumor cells expressing NY-ESO-1 (CTAG1B) or LAGE-1a (Ann Oncol 34 (2023): S1158, NCI Thesaurus). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C213073 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
MDG1015 | MDG1015 | 0 | 1 |